Volume 20 Issue 8
Aug.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(8): 1323-1327
LI Xue-dong, HU Ye-mei, WANG Zhen, WU Gang, LI Jun, WU Yong-yuan, SHANG Zhuo. Randomised controlled trial of delayed versus undelayed bivalirudin in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention[J]. Chinese Journal of General Practice, 2022, 20(8): 1323-1327. doi: 10.16766/j.cnki.issn.1674-4152.002587
Citation: LI Xue-dong, HU Ye-mei, WANG Zhen, WU Gang, LI Jun, WU Yong-yuan, SHANG Zhuo. Randomised controlled trial of delayed versus undelayed bivalirudin in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention[J]. Chinese Journal of General Practice, 2022, 20(8): 1323-1327. doi: 10.16766/j.cnki.issn.1674-4152.002587
shu

Randomised controlled trial of delayed versus undelayed bivalirudin in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

doi: 10.16766/j.cnki.issn.1674-4152.002587

  • Department of Cardiovascular Medicine, the Second People's Hospital of Bengbu, Bengbu, Anhui 233000, China

Funds:

 AHWJ2021b095

 20190338

  • Received Date: 2022-02-22
    Available Online: 2022-09-26
    Abstract
  •   Objective  To evaluate the efficacy and safety of undelayed bivalirudin combined with intracoronary tirofiban only during primary percutaneous coronary intervention (PCI) in patients with acute elevation myocardial infarction (AMI).  Methods  A total of 150 patients with AMI admitted to the Department of Cardiology, Bengbu Second People's Hospital from April 2020 to March 2021 were selected and randomly divided into two groups: the experimental group (n=75) and the control group (n=75). Postoperative TIMI flow grade (TFG), corrected TIMI frame count(cTFC), 90 min postoperative ST segment resolution (STR), postoperative cardiac function parameters, any bleeding events and major adverse cardiovascular events (MACEs) after 30 days were recorded and analysed after completion of primary PCI.  Results  No significant differences between the two groups were found in terms of the TFG, cTFC, STR (Z=0.524, P=0.770), MACE (1.3% vs. 0, P=0.999), left ventricular ejection fraction [(49.5±6.6)% vs. (50.6±5.7) %, t=-1.092, P=0.276], left ventricular end-diastolic dimension [(50.0±8.9) mm vs. (51.2±7.6) mm, t=-0.888, P=0.376] and regional wall motion abnormality (86.7% vs. 90.1%, χ2=0.597, P=0.440). The bleeding events in the experimental group were significantly less than those in the control group, and the difference was statistically significant (5.3% vs. 18.7%, χ2=6.221, P=0.035).  Conclusion  The undelayed bivalirudin combined with intracoronary tirofiban only strategy, which is associated with good safety demonstrated by reduced bleeding events, is an alternative regimen for patients with AMI undergoing primary PCI.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    PATEL H, GARRIS R, BHUTANI S, et al. Bivalirudin versus heparin during percutaneous coronary intervention in patients with acute myocardial infarction[J]. Cardiol Res, 2019, 10(5): 278-284. doi: 10.14740/cr921
    [2]
    HAN Y L, GUO J C, ZHENG Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: The BRIGHT randomized clinical trial[J]. JAMA, 2015, 313(13): 1336-1346. doi: 10.1001/jama.2015.2323
    [3]
    王娟, 范西真, 吴晓飞. 急性冠脉综合征的诊治与管理[J]. 中华全科医学, 2021, 19(7): 1073-1074. http://www.zhqkyx.net/article/id/aa90c0ac-e729-4f80-9cfa-d82edb47ae2e

    WANG J, FAN X Z, WU X F. Diagnosis, treatment and management of acute coronary syndromes[J]. Chinese Journal of General Practice, 2021, 19(7): 1073-1074. http://www.zhqkyx.net/article/id/aa90c0ac-e729-4f80-9cfa-d82edb47ae2e
    [4]
    陈杰, 张斌, 陈丹, 等. 依替巴肽三种给药途径在高血栓负荷急性ST段抬高型心肌梗死PCI中的效果[J]. 中国临床研究, 2022, 35(5): 655-659, 664. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCK202205012.htm

    CHEN J, ZHANG B, CHEN D, et al. Clinical effects of three route of etibatide administration in PCI of acute ST segment elevation myocardial infarction with high thrombotic load[J]. Chinese Journal of Clinical Research, 2022, 35(5): 655-659, 664. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCK202205012.htm
    [5]
    商卓, 罗惟恕, 关杰, 等. 冠状动脉内盐酸替罗非班联合短时静脉泵注对行直接PCI术STEMI患者的疗效评价[J]. 中国急救医学, 2016, 36(5): 430-433.

    SHANG Z, LUO W S, GUAN J. Effects of intracoronary tirofiban plus short duration of infusion administration in patients with ST-segment elevation myocardial infarction after primary pereutaneous coronary intervention[J]. Chinese Journal of Critical Care Medicine, 2016, 36(5): 430-433.
    [6]
    商卓, 庄文文, 郑晓群, 等. 依替巴肽冠状动脉内给药治疗ST段抬高型心肌梗死的疗效评价[J]. 中国心血管杂志, 2016, 21(4): 268-272. https://www.cnki.com.cn/Article/CJFDTOTAL-XIXG201604006.htm

    SHANG Z, ZHUANG W W, ZHENG X Q, et al. Evaluation on the efficacy and safety of intracoronary eptifibatide only during primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction[J]. Chinese Journal of Cardiovascular Medicine, 2016, 21(4): 268-272. https://www.cnki.com.cn/Article/CJFDTOTAL-XIXG201604006.htm
    [7]
    TURAN Y, DEMIR V. The relation of endocan and galectin-3 with ST-segment resolution in patients with ST-segment elevation myocardial infarction[J]. Adv Clin Exp Med, 2020, 29(4): 453-458. doi: 10.17219/acem/118126
    [8]
    CUTLIP D E, URBAN P. Validation of standardization: Testing the academic research consortium high bleeding risk criteria[J]. Circ Cardiovasc Interv, 2019, 12(11): e008569. doi: 10.1161/CIRCINTERVENTIONS.119.008569
    [9]
    ERDOES G, ORTMANN E, MARTINEZ L D A B, et al. Role of bivalirudin for anticoagulation in adult perioperative cardiothoracic practice[J]. J Cardiothorac Vasc Anesth, 2020, 34(8): 2207-2214. doi: 10.1053/j.jvca.2019.08.022
    [10]
    LI J Y, LIU X, MA S C, et al. Effectiveness and safety of bivalirudin in elderly patients with coronary artery disease undergoing percutaneous coronary intervention: A real-world study[J]. Catheter Cardiovasc Interv, 2022. DOI: 10.1002/ccd.30099.
    [11]
    HUANG X, REDFORS B, CHEN S, et al. Predictors of mortality in patients with non-anterior ST-segment elevation myocardial infarction: Analysis from the HORIZONS-AMI trial[J]. Catheter Cardiovasc Interv, 2019, 94(2): 172-180. doi: 10.1002/ccd.28096
    [12]
    SHAH R, LATHAM S B, PORTA J M, et al. Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis[J]. Catheter Cardiovasc Interv, 2019, 94(2): 210-215.
    [13]
    SUN Y, LI C Z, ZHANG L N, et al. Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients[J]. Atherosclerosis, 2019, 290: 52-58.
    [14]
    LOGANATH K, ADAMSON P D, MOSS A J. Ticagrelor in the management of coronary artery disease[J]. Future Cardiol, 2021, 17(4): 561-571.
    [15]
    林伟, 周瑞, 林建锋, 等. 替格瑞洛对急性冠脉综合征氯吡格雷用药低反应性患者的临床疗效观察[J]. 中华全科医学, 2017, 15(6): 934-936. doi: 10.16766/j.cnki.issn.1674-4152.2017.06.007

    LIN W, ZHOU R, LIN J F, et al. Efficacy and loading dose analysis of ticagrelor in acute coronary syndrome patients with low on-clopidogrel platelet reactivity and its influence on prognosis[J]. Chinese Journal of General Practice, 2017, 15(6): 934-936. doi: 10.16766/j.cnki.issn.1674-4152.2017.06.007
    [16]
    GIORDANO A, MUSUMECI G, D ' ANGELILLO A, et al. Effects of glycoprotein Ⅱb/Ⅲa antagonists: Anti platelet aggregation and beyond[J]. Curr Drug Metab, 2016, 17(2): 194-203.
    [17]
    ABDELADIM S, ELHARRAS M, ELOUARRADI A, et al. Thrombocytopenia induced by glycoprotein (GP) Ⅱb-Ⅲa antagonists: About two cases[J]. Pan Afr Med J, 2021, 38(9): 9.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (488) PDF downloads(6) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return